Talis Biomedical Corporation
230 Constitution Drive
Menlo Park, California 94025
May 20, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Michael Davis and Laura Crotty
| RE: | Talis Biomedical Corporation |
Registration Statement on Form S-3
File No. 333-264839
| Acceleration Request | ||||
| Requested Date: | May 24, 2022 | |||
| Requested Time: | 4:00 p.m. Eastern Time | |||
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 (File No. 333-264839) (the “Registration Statement”) to become effective at 4:00 p.m. Eastern Time on May 24, 2022, or as soon thereafter as is practicable.
Once the Registration Statement has been declared effective, please orally confirm that event with Karen Deschaine of Cooley LLP, counsel to the registrant, at (858) 550-6088 or in her absence, Edmond Lay of Cooley LLP at (858) 550-6166. Thank you for your assistance.
| Very Truly Yours, | ||
| TALIS BIOMEDICAL CORPORATION | ||
| By: | /s/ J. Roger Moody, Jr. | |
| J. Roger Moody, Jr. | ||
| Chief Financial Officer | ||